Pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising oligonucleotide as active ingredient
AssigneeInteroligo Corporation
InventorsJung Hwan LEE, Jongook LEE, Se Na LEE, Hanseul PARK
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising an oligonucleotide as an active ingredient.
Claims19
A pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising a modified oligonucleotide having a structure represented by Chemical Formula 1:
- or a pharmaceutically acceptable salt thereof,
- wherein N and M independently are deoxyuridine (dU), deoxycytidine (dC), uridine (U), or cytidine (C) bound with a halogen or hydroxyl at the 5-position or 2′-position;
- x and y are independently integers from 0 to 10, provided that x and y are not both 0;
- n is an integer from 1 to 10;
- and m is an integer from 1 to 10.
A pharmaceutical composition for preventing or treating metastatic cancer or tumors occurring after surgical resection of triple-negative breast cancer, comprising a modified oligonucleotide having a structure represented by Chemical Formula 1:
- or a pharmaceutically acceptable salt thereof,
- wherein the pharmaceutical composition is administered to a subject who has undergone surgical resection of triple-negative breast cancer,
- wherein N and M independently are deoxyuridine (dU), deoxycytidine (dC), uridine (U), or cytidine (C) bound with a halogen or hydroxyl at the 5-position or 2′-position;
- x and y are independently integers from 0 to 10, provided that x and y are not both 0;
- n is an integer from 1 to 10;
- and m is an integer from 1 to 10.
Dependencies are inferred from the claim text.